Skip to content
Clinical Development

[Webinar] Optimizing Study Execution in Obesity Clinical Trials: Considerations for Recruitment and Retention

  • July 26, 2023

Despite increasing awareness of the negative health outcomes associated with obesity, the prevalence of obesity continues to increase both in the US and globally. Recent breakthroughs in the development and approval of novel anti-obesity drugs hold much promise and have reinvigorated this field. However, the management of obesity clinical trials presents unique challenges for effective recruitment and retention of participants.

Unlike many trials in chronic diseases, obesity trials often attract motivated individuals who are eager to achieve rapid weight loss. Given that screening and enrollment rates can be higher than in most other metabolic indications, it is essential to effectively handle the high volume of subject visits, data collection and ensure data integrity, proactive planning and prompt monitoring visits. Minimizing patient dropouts and maximizing retention is also critical for the success of obesity clinical trials. Dropout rates in obesity studies have historically been as high as 50 percent, primarily due to factors such as perceived lack of efficacy, tolerability issues with study drugs and the availability of alternative treatment options.

Watch the webinar below to hear from Medpace medical and operational experts as they address these unique challenges in the recruitment and retention of obesity participants and provide insights into optimizing the execution of research in obesity clinical trials.

The Medpace medicaloperations, and regulatory staff understand the complexities of obesity trials from the perspective of the Sponsor, the clinical investigator, the scientific leader, and the reviewer at the regulatory agencies. Our matured relationships with global thought leaders, investigative sites, the Medpace global ‘flagship’ metabolic site network, and patient advocacy groups, as well as knowledge of effective patient retention strategies, ensure efficient and quality patient enrollment which is key to the success of these programs.

In addition to therapeutically specialized, full-service CRO offerings, Medpace provides comprehensive and fully integrated global central lab services, a bioanalytical lab, an imaging core lab, an ECG core lab, and a Phase I unit. The built-in collaboration and efficiencies of working with a single vendor facilitates a streamlined strategy for executing trials of all sizes and scope.

Learn more about Medpace’s obesity capabilities.